Component
Plasma cerivastatin exposure
Circulating cerivastatin, its lactone and metabolites.
2 recorded relationships. Experimental role, claim status and evidence remain attached to each record.
How nutrients influence it
Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.
Other things that act on it
Enzymes, hormones, genes, and other components with a recorded effect. These are not nutrients, so they do not count toward the arrows above. Each finding names the chapter that recorded it.
How nutrients reach it in more than one step
Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.
Tracing routes…
What it does
Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.
What it acts on
Concomitant use of gemfibrozil with statins, and particularly with cerivastatin, increases the risk of rhabdomyolysis, and this study was undertaken because the mechanism of that potentially fatal interaction was unclear.
Experimental context and source evidence
- duration
- Not applicable
- evidence_access
- Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.
- experimental_model
- Stated as the background to a 10-volunteer pharmacokinetic study
- exposure
- Gemfibrozil with cerivastatin
- limitations
- This is the study's framing of an established clinical association rather than a measurement made in it; no muscle outcome was recorded in the ten volunteers.
- organism
- Stated as the background to a 10-volunteer pharmacokinetic study
- plain_language
- Concomitant use of gemfibrozil with statins, and particularly with cerivastatin, increases the risk of rhabdomyolysis, and this study was undertaken because the mechanism of that potentially fatal interaction was unclear.
- primary_references
- Gemfibrozil greatly increases plasma concentrations of cerivastatin. (2002). https://pubmed.ncbi.nlm.nih.gov/12496749/ DOI: 10.1067/mcp.2002.128469
- route
- Oral
- tissue
- Skeletal muscle injury risk during combined treatment
Statin plasma exposure and muscle injury: dose randomisation and a drug interaction (2026-09-22) · lines 57–66
Original AI-assisted curation of three primary studies resolved by PubMed title search and cross-checked against live PubMed metadata. Two share a research group with the OATP1B1 collection and are recorded as one line of evidence with it. Study-specific doses, effect sizes and limitations retained. Not publisher full text. · supports · · source_derived_draft · unverified_draft
## cerivastatin-exposure-and-rhabdomyolysis-risk Concomitant use of gemfibrozil with statins, and particularly with cerivastatin, increases the risk of rhabdomyolysis, and this study was undertaken because the mechanism of that potentially fatal interaction was unclear. Model/species: Stated as the background to a 10-volunteer pharmacokinetic study Tissue/system: Skeletal muscle injury risk during combined treatment Exposure: Gemfibrozil with cerivastatin Route: Oral Duration: Not applicable Limits: This is the study's framing of an established clinical association rather than a measurement made in it; no muscle outcome was recorded in the ten volunteers. Primary reference: Gemfibrozil greatly increases plasma concentrations of cerivastatin. (2002). https://pubmed.ncbi.nlm.nih.gov/12496749/ DOI: 10.1067/mcp.2002.128469 Access: Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.
Complete structured claim and evidence
What acts on it
Gemfibrozil raised the plasma exposure of cerivastatin to 559 percent of control, with a range across subjects of 138 to 995 percent.
Experimental context and source evidence
- duration
- 3 days of gemfibrozil, 24 hours of sampling
- evidence_access
- Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.
- experimental_model
- 10 healthy volunteers, randomised double-blind crossover
- exposure
- Gemfibrozil 600 mg twice daily for 3 days, then a single 0.3 mg cerivastatin dose
- limitations
- Metabolite M-23 exposure fell to 22 percent of control while the parent and other metabolites rose, so the interaction shifts the metabolic route rather than simply slowing clearance. Between-subject variation was wide.
- organism
- 10 healthy volunteers, randomised double-blind crossover
- plain_language
- Gemfibrozil raised the plasma exposure of cerivastatin to 559 percent of control, with a range across subjects of 138 to 995 percent.
- primary_references
- Gemfibrozil greatly increases plasma concentrations of cerivastatin. (2002). https://pubmed.ncbi.nlm.nih.gov/12496749/ DOI: 10.1067/mcp.2002.128469
- route
- Oral
- tissue
- Plasma cerivastatin, cerivastatin lactone and its metabolites
Statin plasma exposure and muscle injury: dose randomisation and a drug interaction (2026-09-22) · lines 46–55
Original AI-assisted curation of three primary studies resolved by PubMed title search and cross-checked against live PubMed metadata. Two share a research group with the OATP1B1 collection and are recorded as one line of evidence with it. Study-specific doses, effect sizes and limitations retained. Not publisher full text. · supports · · source_derived_draft · unverified_draft
## gemfibrozil-raises-cerivastatin-exposure Gemfibrozil raised the plasma exposure of cerivastatin to 559 percent of control, with a range across subjects of 138 to 995 percent. Model/species: 10 healthy volunteers, randomised double-blind crossover Tissue/system: Plasma cerivastatin, cerivastatin lactone and its metabolites Exposure: Gemfibrozil 600 mg twice daily for 3 days, then a single 0.3 mg cerivastatin dose Route: Oral Duration: 3 days of gemfibrozil, 24 hours of sampling Limits: Metabolite M-23 exposure fell to 22 percent of control while the parent and other metabolites rose, so the interaction shifts the metabolic route rather than simply slowing clearance. Between-subject variation was wide. Primary reference: Gemfibrozil greatly increases plasma concentrations of cerivastatin. (2002). https://pubmed.ncbi.nlm.nih.gov/12496749/ DOI: 10.1067/mcp.2002.128469 Access: Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.
Complete structured claim and evidence
The events it takes part in
A mechanism often involves more than two components. These are the full events, with every participant and its role.
Situations it appears in
Low-supply and faulty-machinery situations recorded in the chapters where this component plays a part.
In the sources
Preserved passages that mention this component, quoted exactly. Open one to read it in context.
Open hypotheses
Proposed ideas that involve this component. They are labeled as hypotheses and do not change any recorded statement.
This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.